[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642190":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":10,"responsibleParty":19,"collaborators":10,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":26,"acronym":10,"eligibilityCriteria":27,"healthyVolunteers":23,"sex":28,"minAge":29,"maxAge":10,"enrollmentInfo":30,"targetDuration":33,"studyType":34,"phases":10,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"QL1706-based therapy (with or without chemotherapy\u002Fbevacizumab)",null,{"label":12,"type":10,"description":10,"interventionNames":10},"investigator-selected chemotherapy (with or without bevacizumab)",[14],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"peng Li","CONTACT","+86 18560082010","peng_li2002@163.com",{"type":20,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642190","tte-study-of-ql1706-in-recurrentmetastatic-cervical-cancer-100642190",false,"NCT07652983","TTE Study of QL1706 in Recurrent\u002FMetastatic Cervical Cancer","Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Participants voluntarily agree to participate in the study and provide written informed consent.\n* Age ≥18 years at the time of signing the informed consent form.\n* Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* Disease progression or treatment failure following prior platinum-based chemotherapy.\n* At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI.\n* Estimated life expectancy of at least 3 months.\n* Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706.\n\nExclusion Criteria:\n\n* Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies.\n* History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and\u002For any of its excipients.\n* Known additional malignancy that has progressed or required active treatment within the past 3 years.\n* Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis.\n* Active infection requiring systemic therapy.\n* Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","FEMALE","18 Years",{"count":31,"type":32},280,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment.\n\nThe main questions it aims to answer are:\n\n* Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer?\n* Does the addition of bevacizumab further improve treatment effectiveness?\n* Which patient subgroups are most likely to benefit from QL1706-based therapy? Participants receiving QL1706-based therapy or investigator-selected chemotherapy as part of routine clinical practice will be followed through real-world clinical data collection. Using a target trial emulation framework, the study will compare treatment effectiveness and safety between groups. Clinical characteristics, treatment outcomes, and adverse events will be collected for analysis. In addition, artificial intelligence-based models and multi-omics analyses will be used to identify predictive biomarkers and explore potential mechanisms of treatment response and resistance.",[37],"Recurrent or Metastatic Cervical Cancer",[39,40],"Recurrent or metastatic cervical cancer","Iparomlimab and Tuvonralimab","NOT_YET_RECRUITING","2026-06-11",{"date":44,"type":45},"2026-06-17","ACTUAL",{"date":47,"type":32},"2026-06-15",{"date":49,"type":32},"2029-12-31",{"name":5,"class":6}]